BioNTech SE (BNTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

BioNTech SE (BNTX) closed at USD 90.20 on 2026-10-15, a change of -12.7 % over the past year, with a market capitalization of USD 22.03B.

BioNTech SE recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

BioNTech SE key figures

Previous close

USD 90.20 (2026-10-15)

1-year change

-12.7 %

Market cap

USD 22.03B

Enterprise value

USD 8.89B

P/E ratio (trailing)

-11.20

P/E ratio (forward)

-15.65

EPS (trailing)

-7.83

EPS (forward)

-5.60

PEG ratio

0.05

Price to book

1.11

Revenue growth

-59.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

2.85

Employees

7,807

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About BioNTech SE

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for BioNTech SE and compare it with other stocks.